eGFR 45 mL/min/1.73 m²: Classification and Management
An eGFR of 45 mL/min/1.73 m² indicates moderately reduced kidney function (CKD G3a) and requires immediate assessment of albuminuria to determine cardiovascular and kidney disease risk, followed by initiation of SGLT-2 inhibitors in most patients.
CKD Classification
An eGFR of 45 mL/min/1.73 m² places the patient in CKD category G3a (mildly to moderately decreased GFR: 45-59 mL/min/1.73 m²) 1. This represents a critical threshold where management decisions become heavily dependent on albuminuria status.
Risk Stratification
The next essential step is measuring the albumin-to-creatinine ratio (ACR) to complete risk stratification 2:
- Moderate risk: eGFR 45-59 with ACR <3 mg/mmol (<30 mg/g)
- High risk: eGFR 45-59 with ACR 3-30 mg/mmol (30-299 mg/g)
- Very high risk: eGFR 45-59 with ACR >30 mg/mmol (≥300 mg/g)
This classification directly determines treatment intensity and monitoring frequency.
Core Management Recommendations
SGLT-2 Inhibitors
For patients with eGFR 45-59 and ACR <3 mg/mmol: Consider SGLT-2 inhibitor therapy (weak recommendation) 2.
For patients with eGFR 45-59 and ACR ≥3 mg/mmol: Strongly recommend SGLT-2 inhibitor initiation 2, 3. The 2024 KDIGO guideline provides high certainty evidence for overall survival benefit and reduced kidney failure risk in this population. SGLT-2 inhibitors should be continued even if eGFR subsequently drops below 20 mL/min/1.73 m² unless dialysis is initiated 3.
RAS Inhibition
Start ACE inhibitor or ARB if albuminuria is present 3:
- Mandatory for ACR ≥30 mg/mmol (A3 category) - strong recommendation
- Suggested for ACR 3-30 mg/mmol (A2 category) - conditional recommendation
Use the highest tolerated approved dose. Monitor serum creatinine and potassium within 2-4 weeks of initiation. Continue therapy even if creatinine rises up to 30% within 4 weeks, unless symptomatic hypotension or uncontrolled hyperkalemia develops 3.
Blood Pressure Management
Target office BP <120/80 mmHg if tolerated without symptoms of hypotension. This applies regardless of diabetes status when albuminuria is present 3.
Monitoring Schedule
Based on the 2022 Mayo Clinic diabetic kidney disease guideline 4:
- eGFR 45-59 with ACR <3 mg/mmol (moderate risk): Monitor twice yearly
- eGFR 45-59 with ACR 3-30 mg/mmol (high risk): Monitor twice yearly
- eGFR 45-59 with ACR >30 mg/mmol (very high risk): Monitor 3 times yearly
Each visit should include serum creatinine, eGFR calculation, electrolytes (particularly potassium), and urine ACR.
Nephrology Referral
Consider nephrology referral for patients with eGFR 45-59 and ACR >30 mg/mmol, though this may be managed in primary care depending on local resources and expertise 4. Mandatory referral becomes necessary if eGFR drops below 30 mL/min/1.73 m² 5.
Medication Adjustments
At eGFR 45 mL/min/1.73 m²:
- Metformin: Review use and consider risk-benefit; suspend if patient becomes acutely ill 5
- Tetracyclines: Reduce dose; can exacerbate uremia 5
- Antifungals: Reduce fluconazole maintenance dose by 50% 5
- NSAIDs: Avoid prolonged therapy 5
Critical Pitfalls
Do not discontinue ACE inhibitors or ARBs solely because eGFR is 45 mL/min/1.73 m². These remain nephroprotective and should be continued unless specific contraindications develop (>30% creatinine rise, symptomatic hypotension, or refractory hyperkalemia) 3.
Do not delay SGLT-2 inhibitor initiation in patients with albuminuria. The 2024 BMJ guideline demonstrates moderate-to-high certainty evidence for mortality reduction and cardiovascular benefit, with the reversible eGFR dip upon initiation not being an indication to stop therapy 2.
Age considerations: While eGFR 45 mL/min/1.73 m² may represent normal age-related decline in adults >70 years 6, 7, the presence of albuminuria still mandates treatment as cardiovascular and mortality risks remain elevated regardless of age 8.